Core Viewpoint - The company, He Yu-B (02256), announced that its subsidiary, Shanghai He Yu Biopharmaceutical Technology Co., Ltd., has received Orphan Drug Designation (ODD) from the FDA for its orally administered small molecule FGFR2/3 inhibitor, ABSK061, aimed at treating Achondroplasia (ACH) [1][2][3] Group 1: Product Development - ABSK061 is a highly selective and potent small molecule FGFR2/3 inhibitor, showing strong target inhibition activity and promising pharmacokinetic and safety profiles in preclinical studies [2][3] - The oral administration route is expected to significantly enhance treatment convenience and compliance, particularly for pediatric patients [2] - ABSK061 is currently undergoing a Phase II clinical trial for ACH patients aged 3-12, with the first patient dosed in December 2025 and preliminary data expected in the second half of 2026 [2] Group 2: Regulatory Milestones - The receipt of ODD is a significant milestone that supports the clinical development, registration, and commercialization processes in the U.S. [1] - ODD designation provides multiple potential benefits, including tax credits for clinical trials, fee waivers for NDA/BLA submissions, and a potential seven-year market exclusivity post-approval [1] - The recognition of ABSK061's potential clinical value by the FDA underscores the unmet medical need for ACH treatment [1] Group 3: Market Potential - Achondroplasia is a rare autosomal genetic disorder leading to severe growth and developmental issues, primarily caused by mutations in the FGFR3 gene [1] - Targeted inhibitors like ABSK061 are expected to offer more precise and effective treatment options for ACH patients [1][3] - The development of ABSK061 as a next-generation FGFR inhibitor aims to achieve a broader therapeutic window and improved clinical efficacy compared to first-generation pan-FGFR inhibitors [3]
和誉-B(02256)：FGFR2/3抑制剂ABSK061 获FDA授予孤儿药资格认定 用于治疗软骨发育不全